Efficacy of levofloxacin-based third-line therapy for the eradication of helicobacter pylori in peptic ulcer disease

Joo Hyun Lim, Sang Gyun Kim, Ji Hyun Song, Jae Jin Hwang, Dong Ho Lee, Jae Pil Han, Su Jin Hong, Ji Hyun Kim, Seong Woo Jeon, Gwang Ha Kim, Ki Nam Shim, Woon Geon Shin, Tae Ho Kim, Sun Moon Kim, Il Kwon Chung, Hyun Soo Kim, Heung Up Kim, Joongyub Lee, Jae Gyu Kim

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a protonpump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/ gastroduodenal ulcer, 68.8%, p=0.655). Conclusions: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.

Original languageEnglish
Pages (from-to)226-231
Number of pages6
JournalGut and Liver
Issue number2
StatePublished - Mar 2017

Bibliographical note

Funding Information:
This study was supported by a grant (14172MFDS178) from Ministry of Food and Drug Safety in 2014.


  • Helicobacter pylori
  • Levofloxacin
  • Third-line eradication


Dive into the research topics of 'Efficacy of levofloxacin-based third-line therapy for the eradication of helicobacter pylori in peptic ulcer disease'. Together they form a unique fingerprint.

Cite this